Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

• Published in: Frontiers in pharmacology 2018-05, Vol.9, p.536-536
• Main Authors: Wang, Yiting, Wang, Huanbin, Yao, Han, Li, Chushu, Fang, Jing-Yuan, Xu, Jie
• Format: Article
• Language: English
• Subjects: gene expression; immunotherapy; PD-L1; Pharmacology; post-translational modification; small molecular inhibitors
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2018.00536

Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1) and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited momentous clinical benefits and durable responses in multiple tumor types. However, primary resistance is found in considerable number of cancer patients, and most responders eventually develop acquired resistance to ICBT. To tackle these challenges, it is essential to understand how PD-L1 is controlled by cancer cells to evade immune surveillance. Recent research has shed new light into the mechanisms of PD-L1 regulation at genetic, epigenetic, transcriptional, translational, and posttranslational levels. In this work, we systematically discuss the mechanisms that control the gene amplification, epigenetic alteration, transcription, subcellular transportation and posttranscriptional modification of PD-L1 in cancer cells. We further categorize posttranscriptional PD-L1 regulations by the molecular modification of PD-L1, including glycosylation, phosphorylation, ubiquitination, deubiquitination, and lysosomal degradation. These findings may provide new routes for targeting tumor immune escape and catalyze the development of small molecular inhibitors of PD-L1 in addition to existing antibody drugs.